Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02711137 · ClinicalTrials.gov registry record · Phase 1
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 137
- Enrollment target
NCT02711137 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 137 participants.
The verdict
NCT02711137, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types including solid tumors, lymphomas and other hematologic malignancies. Part 3 will determine the tolerated dose of INCB057643 in combination with select SOC agents; and assess the safety and tolerability of the combination therapy in select advanced solid tumors and hematologic malignancies. Part 4 will further evaluate the safety, preliminary efficacy, PK, and PD of the selected dose combination from Part 3 in 4 specific advanced solid tumor and hematologic malignancies.
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Abiraterone
- DRUG Rucaparib
- DRUG INCB057643
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2016-05-18 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02711137
The ClinicalTrials.gov registry entry for NCT02711137 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Paclitaxel is the first listed.
NCT02711137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02711137 about?
NCT02711137 is a clinical study titled "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies". The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose ...
What is the current status of trial NCT02711137?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2016-05-18. Estimated completion is 2019-02-13.
What interventions are being tested in trial NCT02711137?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), Abiraterone (DRUG), Rucaparib (DRUG), INCB057643 (DRUG).
Who is sponsoring clinical trial NCT02711137?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.